eGFR - Use beyond the evidence

Medical Journal of Australia

Volumn 190, Issue 4, 2009, Pages 197-199

  Martin, Jennifer H ^a,b,c   Fay, Michael F ^b   Ungerer, Jacobus P ^a  

^a Pathology Queensland ^*  (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; ENOXAPARIN;

ALGORITHM; ARTICLE; AUSTRALIA; BODY SIZE; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DOSE CALCULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG RESPONSE; EVIDENCE BASED PRACTICE; GLOMERULUS FILTRATION RATE; HUMAN; INTERMETHOD COMPARISON; KIDNEY DYSFUNCTION; LEAN BODY WEIGHT; PATIENT SAFETY; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; VALIDATION PROCESS;

EID: 61849155664     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2009.tb02348.x     Document Type: Article

References (22)

1. Rainey PM. Automatic reporting of estimated glomerular filtration rate - jumping the gun? Clin Chem 2006; 52: 2184-2187.
2. Levey AS, Stevens LA, Hostetter T. Automatic reporting of estimated glomerular filtration rate - just what the doctor ordered. Clin Chem 2006; 52: 2188-2193.
3. Mathew TH; Australasian Creatinine Consensus Working Group. Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: a position statement. Med J Aust 2005; 183: 138-141.
4. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 2002; 39 (2 Suppl 1): S1-S266.
5. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-147.
6. Mathew TH, Johnson DW, Jones GRD; Australasian Creatinine Consensus Working Group. Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: revised recommendations. Med J Aust 2007; 187: 459-463.
7. Roos JF, Doust J, Tett SE, Kirkpatrick CM. Diagnostic accuracy of cystatin C compared to serum creatinine for the estimation of renal dysfunction in adults and children - a meta-analysis. Clin Biochem 2007; 40: 383-391.
8. Doust J. Cystatin C versus serum creatinine or MDRD eGFR for estimating the glomerular filtration rate in adults and children (Cochrane review registered title). http://www.cochrane.org/reviews/en/topics/ 89_titles.html (accessed Jan 2009).
9. Thomas MC; Caring for Australasians with Renal Impairment (CARI). The CARI guidelines. Prevention of progression of kidney disease: early detection of patients with kidney disease. Nephrology (Carlton) 2007; 12 Suppl 1: S37-S40.
10. Giles PD, Fiizmaurice DA. Formula estimation of glomerular filtration rate: have we gone wrong? BMJ 2007; 334: 1198-1200.
11. Chadban SJ, Ierino FL. Welcome to the era of CKD and the eGFR [editorial]. Med J Aust 2005; 183: 117-118.
12. National Screening Committee. Criteria for appraising the viability; effectiveness and appropriateness of a screening programme. London: NSC, 2003. http://www.library.nhs.uk/screening/ViewResource.aspx?resID=59772 (accessed Dec 2008).
13. Mathew TH, Johnson DW, Jones GRD; Australasian Creatinine Consensus Working Group. Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: revised recommendations [letter]. Med J Aust 2008; 188: 429-430.
14. Berges A, Laporte S, Epinat M. Anti-factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years old. Br J Clin Pharmacol 2007; 64: 428-438.
15. Green B, Greenwood B, Saltissi D, et al. Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes. Br J Clin Pharmacol 2005; 59: 281-290.
16. Sanchez-Pena P, Hulot JS, Urien S, et al. Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis. Br J Clin Pharmacol 2005; 60: 364-373.
17. National Prescribing Service. Automatic eGFR reporting - its role in screening for kidney disease and drug-dosing decisions. RADAR, 1 Aug 2008. http://www.nps.org.au/health_professionals/publications/ nps_radar/issues/current/august_2008/egfr (accessed Dec 2008).
18. British National Formulary. What's new in BNF 54? Renal function and drugs. http://www.bnf.org/bnf/extra/current/450035.htm (accessed Jan 2008; no longer available).
19. Center for Drug Evaluation and Research. Guidance for industry: pharmacokinetics in patients with impaired renal function - study design, data analysis, and impact on dosing and labeling. Rockville, Md: United States Food and Drug Administration, 1998. http://www.fda.gov/ cber/gdlns/renal.pdf (accessed Dec 2008).
20. Faull R. Prescribing in renal disease. Aust Prescr 2007; 30: 17-20.
21. Harmoinen A, Lehtimaki T, Korpela M, et al. Diagnostic accuracies of plasma creatinine, cystatin C, and glomerular filtration rate calculated by the Cockcroft-Gault and Levey (MDRD) formulas. Clin Chem 2003; 49: 1223-1225.
22. Kallner A, Ayling PA, Khatami Z. Does eGFR improve the diagnostic capability of S-Creatinine concentration results? A retrospective population based study. Int J Med Sci 2008; 5: 9-17.